Stevanato Group S.p.A.
Stevanato Group S.p.A. is an Italy-based healthcare packaging and device company that supplies drug containment, delivery, and diagnostic solutions to pharmaceutical, biotechnology, and life sciences customers. Its business combines specialty glass and plastic packaging, drug delivery systems, in-vitro diagnostic products, and engineering services across the drug development and commercial supply chain.
Fiscal year 2025 · change from previous year
Development 2022–2025
Business
Share of revenuePrimary packaging such as vials, cartridges, syringes, and related containment products for injectable drugs.
Drug delivery, diagnostic, and other healthcare solutions sold to pharma and diagnostics customers.
Custom machinery, line integration, and customer-specific construction projects for pharmaceutical production.
Diagnostic components and related products used in laboratory and testing workflows.
Customers
Stevanato sells to pharmaceutical, biotechnology, and life sciences companies that need high-integrity primary packaging and delivery systems. It also serves diagnostics customers and drug manufacturers that require custom engineering, technical collaboration, and validated supply capability across development and commercial production. End markets highlighted in the reports include biologics, vaccines, insulin, small molecules and generics, and molecular diagnostics.
Buy vials, syringes, cartridges, and delivery systems for commercial drug supply.
Buy containment and delivery solutions for biologics, including high-value injectable therapies.
Buy in-vitro diagnostic products and components used in testing workflows.
Buy engineering services and integrated solutions for development and scale-up.
Exposure to vaccines, insulin, small molecules, generics, and molecular diagnostics demand.
Strategy
Stevanato Group focuses on integrated solutions that preserve drug integrity, reduce time to market, and lower total cost of ownership for customers. Its strategy is built around co-developing products with customers, leveraging scientific and engineering capabilities, and participating across both direct markets such as drug containment and end markets such as biologics and diagnostics.
Customers value suppliers that can support packaging, delivery, diagnostics, and engineering together.
Co-development helps secure long-term programs and tighter technical integration with pharma customers.
These end markets drive demand for advanced containment and delivery solutions.
Geography
The group is headquartered in Piombino Dese, near Padua, Italy, and operates as an Italian multinational with a global customer base. Its manufacturing and commercialization footprint serves pharmaceutical and diagnostics customers across major healthcare markets, with business exposure tied to where injectable drugs and diagnostic products are developed and produced. The reports do not provide an authoritative revenue-by-country split in the supplied excerpts.
Risks
The business depends on pharmaceutical development cycles, customer qualification, and the adoption of specific drug formats, which can delay projects or shift demand across product categories. It also faces manufacturing, quality, and supply-chain execution risk because its products are tightly integrated into regulated healthcare supply chains. Accounting estimates around variable consideration, contract assets/liabilities, and impairment testing can materially affect reported results when projects change or customer volumes move.
- Customer program timing and qualification delaysImpact: HighLikelihood: Medium
Customers buy validated packaging and delivery systems tied to drug development and launch milestones.
Exposure: Drug containment and engineering projects
- Manufacturing quality and regulatory complianceImpact: HighLikelihood: Medium
Products are used in sterile and regulated healthcare applications, where defects can disrupt customer supply.
Exposure: Primary packaging and drug delivery systems
- Project execution on customer-specific construction contractsImpact: MediumLikelihood: Medium
Engineering revenues depend on delivery, scope control, and milestone achievement on custom contracts.
Exposure: Engineering segment
- Demand mix shifts in biologics, vaccines, and GLP-related productsImpact: MediumLikelihood: Medium
The company’s end markets can change as drug pipelines, launches, and therapeutic preferences evolve.
Exposure: End-market demand
Accounting
Judgemental itemsEngineering contracts use over-time recognition while product sales may be recognized at delivery.
Impact: Affects quarterly revenue and working capital balances
Management estimates expected rebates or adjustments using updated information.
Impact: Can change reported sales and margins
Customer-specific construction and diagnostic activities create timing differences between billing and revenue.
Impact: Affects balance sheet and cash conversion
Goodwill and non-current assets require judgment when indicators arise.
Impact: Could create non-cash charges if assumptions weaken
Similar listed companies
Publicly listed companies with a comparable business focus.
LeonaBio, Inc.
LONA · Biological Products, (No Diagnostic Substances)
West Pharmaceutical Services, Inc
WST · Surgical & Medical Instruments & Apparatus
West Pharmaceutical Services is a U.S.-based manufacturer of containment and delivery systems used with injectable drugs and healthcare products.
Inovio Pharmaceuticals, Inc
INO · Pharmaceutical Preparations
INOVIO Pharmaceuticals is a clinical-stage biotechnology company developing DNA medicines designed to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases.
Monte Rosa Therapeutics, Inc.
GLUE · Biological Products, (No Diagnostic Substances)
Monte Rosa Therapeutics is a biotechnology company developing small-molecule molecular glue degraders (MGDs) that use the cell’s own protein-destruction…
Liminatus Pharma, Inc.
LIMN · Biological Products, (No Diagnostic Substances)
BioNTech SE
BNTX · Biological Products, (No Diagnostic Substances)
BioNTech SE is a biotechnology company focused on discovering and developing immunotherapies and other medicines, with a major commercial base in COVID-19 vaccines and a growing oncology pipeline.
Last updated: 28/09/2026